Q-omics provides the consensus-scored RPL23AP19 profile across patient tissues and cancer cell-line models. RPL23AP19 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPL23AP19 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, RPL23AP19 RNA expression shows 6,479 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, COAD, and STAD as cancer lineages where RPL23AP19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL23AP19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL23AP19 survival associations across molecular data types. RPL23AP19 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL23AP19 RNA expression–survival associations across cancer types. High RPL23AP19 expression shows unfavorable associations in KIRC, OV, BLCA, THCA and UCS, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify KIRC as the clearest survival context for RPL23AP19 RNA expression.
This table summarizes RPL23AP19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL23AP19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL23AP19 shows lower tumor expression in THCA, LUSC and KIRP and higher tumor expression in COAD, LUAD and BRCA. The COAD box plot shows higher RPL23AP19 RNA expression in tumor versus normal tissue (log2 FC = +0.250, t-test p = .001).
This table shows molecular features associated with RPL23AP19 in patient tissues and cancer cell lines. In patient samples, RPL23AP19 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
